Sunshine Biopharma Inc. (NASDAQ: SBFM)

Sunshine Biopharma Inc. operates as a pharmaceutical company, focusing on the development and commercialization of life-saving medicines across various therapeutic areas, including oncology and antivirals. The company's operations are primarily centered in Canada, where it has established two wholly-owned subsidiaries: Nora Pharma Inc. and Sunshine Biopharma Canada Inc. Nora Pharma Inc. is responsible for the marketing and distribution of generic prescription drugs in Canada, while Sunshine Biopharma Canada Inc. develops and sells over-the-counter (OTC) supplements. Additionally, Sunshine Biopharma Inc. is engaged in proprietary drug development programs, targeting liver cancer and SARS Coronavirus infections.

The company generates revenue through the sale of its generic prescription drugs and OTC supplements. Nora Pharma Inc. currently has 70 generic prescription drugs on the market in Canada, with an additional 64 drugs in its pipeline. These drugs cater to a wide range of therapeutic areas, including cardiovascular, oncology, gastroenterology, central nervous system, diabetes, urology, endocrinology, anti-infective, and anti-inflammatory. The primary customer base for these products includes pharmacies and healthcare providers across Canada. The OTC supplements, such as Essential-9, Calcium-Vitamin D, L-Citrulline, and Taurine, are sold through online platforms like Amazon.com and Amazon.ca, catering to health-conscious consumers in the U.S. and Canada.

• Nora Pharma Inc.: This subsidiary focuses on the acquisition, marketing, and distribution of generic prescription drugs in Canada. Nora Pharma Inc. secures rights to pharmaceutical products through in-licensing and supply agreements, cross-licensing, and distribution agreements. The company currently has 70 generic prescription drugs on the market, with an additional 64 drugs in its pipeline. These drugs cater to various therapeutic areas, including cardiovascular, oncology, gastroenterology, central nervous system, diabetes, urology, endocrinology, anti-infective, and anti-inflammatory. The primary customer base for these products includes pharmacies and healthcare providers across Canada.

• Sunshine Biopharma Canada Inc.: This subsidiary develops and sells OTC supplements in Canada. The company currently has four NPNs issued by Health Canada, authorizing the manufacture and sale of its OTC products, including Essential-9, Calcium-Vitamin D, L-Citrulline, and Taurine. These products cater to health-conscious consumers in Canada and are sold through online platforms like Amazon.ca.

• Proprietary Drug Development: Sunshine Biopharma Inc. is engaged in proprietary drug development programs targeting liver cancer and SARS Coronavirus infections. The company's lead drug candidates include K1.1 mRNA, an LNP encapsulated mRNA targeted for liver cancer, and SBFM-PL4, a protease inhibitor for the treatment of SARS Coronavirus infections. These drug candidates are currently in the animal testing phase.

Sunshine Biopharma Inc. operates in a highly competitive industry, with numerous players in the Canadian generic pharmaceuticals market. According to Research and Markets, the Canadian generic pharmaceuticals market was valued at approximately $9.7 billion USD in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 7.9%, reaching $19.2 billion USD by the end of 2032. The company faces competition from more than 35 active generic players in the Canadian market, with the top three holding approximately 50% share of the total market. Despite being a relatively new entrant, Nora Pharma has demonstrated one of the fastest year-over-year sales growth amongst its peers.

In the area of proprietary drug development, Sunshine Biopharma Inc. competes with large publicly and privately held companies engaged in developing new cancer therapies and antiviral treatments. Key competitors include Pfizer, Merck, Amgen, Roche, Pfizer, Bristol-Myers Squibb, Novartis, Gilead, Eli Lilly, and Regeneron. The company's competitive advantages include its focus on developing innovative treatment options that target different parts of the virus or cancer cells, potentially forming an important component of the range of treatment options available to attending physicians.

The primary customer base for Sunshine Biopharma Inc.'s generic prescription drugs includes pharmacies and healthcare providers across Canada. The company's OTC supplements cater to health-conscious consumers in the U.S. and Canada, who purchase these products through online platforms like Amazon.com and Amazon.ca. The proprietary drug development programs are aimed at addressing unmet medical needs in the areas of oncology and antiviral treatments, potentially benefiting a broad range of patients worldwide.